BACKGROUND: Antiplatelet agents are widely used for cardiovascular disea ses, but their pleiotropic effects in sepsis are controversial. OBJECTIVE: To investigate the association between antiplatelet agents and the survival benefit for sepsis patients. DESIGN: A nationwide population-based cohort and nested case-control study. SETTING: Taiwan National Health Insurance database. PARTICIPANTS: All patients (age ≥18 years) who were hospitalized for sepsis between January 2000 and December 2010. MEASUREMENTS: Conditional logistic regression was used to adjust for confounding. Adjusted odd ratios (ORs) were used to compare the mortality rate due to sepsis in antiplatelet drug users and nonusers. RESULTS: Of 683,421 included patients, 229,792 (33.6 %) patients died during hospitalization for sepsis, and the rest (64.4 %) survived to discharge. Use of antiplatelet agents before admission was associated with a lower risk of mortality in sepsis patients (aOR 0.82, 95 % confidence interval [CI] 0.81-0.83, P < 0.001). By using another case-control study design, the beneficial effect was more significant in current users (aOR 0.78, 95 % CI 0.76-0.79) than in recent users (aOR 0.88, 95 % CI 0.85-0.91), but was not significant in past users (aOR 1.00, 95 % CI 0.98-1.02). LIMITATIONS: Observational study. CONCLUSIONS: Prior use of antiplatelet agents was associated with a survival benefit in sepsis patients.
BACKGROUND: Antiplatelet agents are widely used for cardiovascular disea ses, but their pleiotropic effects in sepsis are controversial. OBJECTIVE: To investigate the association between antiplatelet agents and the survival benefit for sepsispatients. DESIGN: A nationwide population-based cohort and nested case-control study. SETTING: Taiwan National Health Insurance database. PARTICIPANTS: All patients (age ≥18 years) who were hospitalized for sepsis between January 2000 and December 2010. MEASUREMENTS: Conditional logistic regression was used to adjust for confounding. Adjusted odd ratios (ORs) were used to compare the mortality rate due to sepsis in antiplatelet drug users and nonusers. RESULTS: Of 683,421 included patients, 229,792 (33.6 %) patients died during hospitalization for sepsis, and the rest (64.4 %) survived to discharge. Use of antiplatelet agents before admission was associated with a lower risk of mortality in sepsispatients (aOR 0.82, 95 % confidence interval [CI] 0.81-0.83, P < 0.001). By using another case-control study design, the beneficial effect was more significant in current users (aOR 0.78, 95 % CI 0.76-0.79) than in recent users (aOR 0.88, 95 % CI 0.85-0.91), but was not significant in past users (aOR 1.00, 95 % CI 0.98-1.02). LIMITATIONS: Observational study. CONCLUSIONS: Prior use of antiplatelet agents was associated with a survival benefit in sepsispatients.
Authors: B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal Journal: JAMA Date: 2001-10-17 Impact factor: 56.272
Authors: Corinne Alberti; Christian Brun-Buisson; Sylvie Chevret; Massimo Antonelli; Sergey V Goodman; Claudio Martin; Rui Moreno; Ana R Ochagavia; Mark Palazzo; Karl Werdan; Jean Roger Le Gall Journal: Am J Respir Crit Care Med Date: 2004-11-05 Impact factor: 21.405
Authors: G R Bernard; A P Wheeler; J A Russell; R Schein; W R Summer; K P Steinberg; W J Fulkerson; P E Wright; B W Christman; W D Dupont; S B Higgins; B B Swindell Journal: N Engl J Med Date: 1997-03-27 Impact factor: 91.245
Authors: Fabián Jaimes; Gisela De La Rosa; Carlos Morales; Fernando Fortich; Clara Arango; Daniel Aguirre; Alvaro Muñoz Journal: Crit Care Med Date: 2009-04 Impact factor: 7.598
Authors: Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2012-01-04 Impact factor: 17.440
Authors: James Trauer; Stephen Muhi; Emma S McBryde; Shmeylan A Al Harbi; Yaseen M Arabi; Andrew J Boyle; Rodrigo Cartin-Ceba; Wei Chen; Yung-Tai Chen; Marco Falcone; Ognjen Gajic; Jack Godsell; Michelle Ng Gong; Daryl Kor; Wolfgang Lösche; Daniel F McAuley; Hollis R O'Neal; Michael Osthoff; Gordon P Otto; Maik Sossdorf; Min-Juei Tsai; Juan C Valerio-Rojas; Tom van der Poll; Francesco Violi; Lorraine Ware; Andreas F Widmer; Maryse A Wiewel; Johannes Winning; Damon P Eisen Journal: Crit Care Med Date: 2017-11 Impact factor: 7.598
Authors: Mark R Thomas; Samuel N Outteridge; Ramzi A Ajjan; Fladia Phoenix; Gurpreet K Sangha; Rachael E Faulkner; Rosemary Ecob; Heather M Judge; Haroon Khan; Laura E West; David H Dockrell; Ian Sabroe; Robert F Storey Journal: Arterioscler Thromb Vasc Biol Date: 2015-10-29 Impact factor: 8.311
Authors: Divyanshu Mohananey; Jaskaran Sethi; Pedro A Villablanca; Muhammad S Ali; Rohit Kumar; Anushka Baruah; Nirmanmoh Bhatia; Sahil Agrawal; Zeeshan Hussain; Fadi E Shamoun; John T Augoustides; Harish Ramakrishna Journal: Ann Card Anaesth Date: 2016 Oct-Dec
Authors: Ni Cheng; Yaping Zhang; M Keegan Delaney; Can Wang; Yanyan Bai; Randal A Skidgel; Xiaoping Du Journal: Nat Commun Date: 2021-05-27 Impact factor: 14.919
Authors: Maryse A Wiewel; Sacha F de Stoppelaar; Lonneke A van Vught; Jos F Frencken; Arie J Hoogendijk; Peter M C Klein Klouwenberg; Janneke Horn; Marc J Bonten; Aeilko H Zwinderman; Olaf L Cremer; Marcus J Schultz; Tom van der Poll Journal: Intensive Care Med Date: 2016-01-14 Impact factor: 17.440